Sean Murphy Buys 15,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Sean Murphy purchased 15,000 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was purchased at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the acquisition, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

TriSalus Life Sciences Stock Up 4.5 %

Shares of TriSalus Life Sciences stock opened at $5.11 on Friday. TriSalus Life Sciences, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $10.42. The firm has a market cap of $155.80 million, a PE ratio of -2.05 and a beta of 0.51. The business’s fifty day moving average is $4.57 and its two-hundred day moving average is $4.75.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group lowered their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus target price of $11.79.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth $92,000. Geode Capital Management LLC raised its position in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the period. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth $108,000. MSD Partners L.P. purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth $184,000. Finally, Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth $66,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.